Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

BACKGROUND: Benralizumab, a monoclonal antibody targeting the human interleukin-5 (IL-5) receptor (IL-5R), was used before marketing authorisation in Spain in a real world setting as part of an early-access programme (EAP) to treat patients with severe eosinophilic asthma with prior insufficient res...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Moragón, Eva, García-Moguel, Ismael, Nuevo, Javier, Resler, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684207/
https://www.ncbi.nlm.nih.gov/pubmed/34922515
http://dx.doi.org/10.1186/s12890-021-01785-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684207/
https://www.ncbi.nlm.nih.gov/pubmed/34922515
http://dx.doi.org/10.1186/s12890-021-01785-z

Ejemplares similares